SwabAi Diagnostics

SwabAi Diagnostics appears to have been a planned molecular diagnostics spinout created by Nova Mentis from its wholly owned subsidiary, Pilz Bioscience. Public disclosures describe the business as focused on mRNA-based, AI-enabled diagnostic technology intended to assess neuroinflammatory status and monitor treatment response in neurological and central nervous system inflammatory disorders. The company was positioned as a standalone diagnostics business rather than a therapeutic developer, with its value proposition centered on biomarker measurement and analytics. However, the available evidence is limited to parent-company announcements about an intended renaming and spinout, and there is little evidence of an independently operating company with an active commercial presence.